View all news

CTSO: CytoSorbents Reaches Positive Operating Cash Flow in the 3rd Quarter

11/17/2026

By Tom Kerr, CFA

NASDAQ: CTSO

READ THE FULL CTSO RESEARCH REPORT

3rd Quarter 2026 Financial Results

On November 12, 2026, CytoSorbents (NASDAQ: CTSO) released 3rd quarter financial and operating results which were largely in line with our expectations. The company achieved an important milestone as they generated positive operating cash flow totaling $43,000.

The company reported 3rd quarter revenue of $9.7 million, up 3% from $9.5 million in Q3 2025, driven by a 16% increase in distributor and strategic partner sales. International sales outside Germany grew 4%. Those two channels accounted for 76% of third quarter sales. Germany represents the remaining 24% and declined approximately 20%-21% year-over-year. This was driven by the reduction of the sales force in that territory during the restructuring period. The large market opportunity is believed to still be intact.

Gross margin improved to 75% from 70% a year earlier, while operating expenses declined 11% to $8.5 million (13% excluding $250,000 in restructuring charges). As a result, the operating loss improved to ($1.2) million. The net loss improved 42% to ($1.8) million, or ($0.58) per share, compared to ($3.2) million, or ($1.01) per share, in the prior-year period. The adjusted EBITDA loss improved to ($0.3) million from ($2.0) million.

Importantly, the company achieved its goal of operating cash flow breakeven, generating approximately $43,000 in positive operating cash flow during the quarter (excluding $251,000 in restructuring-related payments). Total cash burn, including these payments, was approximately $200,000. Management attributed the improvement to disciplined execution, higher gross margins, and a more efficient cost structure, noting that continued reductions in operating cash burn should lower future financing requirements and improve the company's ability to capture the benefits of expected revenue growth.

Total cash and equivalents (including restricted cash) were approximately $5.7 million on September 30, 2026 compared to $5.9 million on June 30, 2026. Going forward, we expect the quarterly cash burn in the near term to be approximately $200,000 per quarter.

Value Drivers

The company reiterated four important value drivers that management believes will drive shareholder value going forward.

1. Achieving Operating Cash Flow Breakeven

This was achieved in the 3rd quarter. The company generated approximately $43,000 in positive operating cash flow (excluding $251,000 in restructuring-related payments), compared with operating cash burn of approximately $200,000 in Q2 2026 on the same basis and $2.7 million in Q3 2025.

The improvement reflects a broad-based effort to streamline operations and strengthen financial performance. Manufacturing efficiencies and improved sourcing increased product gross margin 500 basis points to 75% from 70% a year ago, while a 24% reduction in headcount since September 2025 and disciplined expense management significantly lowered the company's overall cost structure. Working capital also improved, with inventory declining from $5.3 million at year-end 2025 to $3.2 million as of September 30, 2026.

Going forward, management's priority is to sustain operating cash flow at or near breakeven while selectively investing to accelerate sales growth, which has historically been constrained by limited resources. With a leaner cost structure and healthy gross margins, the company believes it is better positioned to capitalize on growth opportunities and generate operating leverage as revenues increase. While quarterly cash flow may fluctuate due to the timing of revenue, collections, and working capital, management remains focused on financial discipline and converting incremental sales growth into improved profitability and long-term shareholder value.

2. Returning CytoSorb to Sustainable, Profitable Growth

The company’s 2nd key value driver is restoring profitable growth in its core CytoSorb franchise. Third-quarter distributor and strategic partner sales increased 18% year-over-year and 10% sequentially, while direct sales outside Germany grew 4%, collectively representing 76% of revenue. These gains were partially offset by a 20% decline in Germany, reflecting reduced sales force capacity and territory coverage following the commercial restructuring. To address this, the company is rebuilding its German sales organization, adding five representatives through early 2027, and recently appointed Alex Tiefenbacher as SVP of Direct Sales to lead its German and international direct sales operations. Management believes these investments in leadership and sales capacity will improve execution, expand market coverage and support a return to sustained revenue growth.

The company's "Right Patient, at the Right Time, with the Right Dose" commercial strategy continues to gain traction, supported by its PuriFi® pump platform and HotSwap® technology, which simplify treatment delivery and encourage earlier, more consistent CytoSorb use. The company is also expanding its clinical evidence base, highlighted by new data presented at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting covering blood thinner removal, post-operative shock, VA-ECMO support, and heart transplantation, as well as findings from the international COSMOS critical care registry presented at the European Society of Intensive Care Medicine (ESICM) LIVES 2026 congress addressing sepsis, liver support, and VV-ECMO. Management believes renewed growth in Germany, continued international momentum, an expanding clinical evidence base, and a leaner cost structure position the core CytoSorb franchise to accelerate revenue growth, leverage attractive gross margins, and translate higher sales into improved profitability and cash flow.

3. Opening the North American Market Through DrugSorb-ATR

An important third value driver is obtaining FDA marketing authorization for DrugSorb-ATR, which is designed to remove commonly prescribed blood thinners during cardiopulmonary bypass in patients requiring urgent coronary artery bypass graft (CABG) and other cardiac surgeries, with the goal of reducing serious bleeding complications. Management estimates an initial addressable market of approximately $300 million in the U.S. and Canada, with potential expansion to $1–$2 billion through additional blood thinners and surgical indications.

During the quarter, the company advanced preparations for a new De Novo submission related to the blood thinner, Brilinta, expected in early 2027, supported by an independent patient-matched analysis of 587 patients that demonstrated a statistically significant 37% reduction in severe bleeding with intraoperative CytoSorb use among patients recently exposed to Brilinta (21.8% versus 34.5% for the control group; p=0.002). The findings also showed significant reductions in chest tube drainage and red blood cell transfusions, with no serious device-related adverse events. The results indicate it would only require 8 patients treated with CytoSorbents’ technology to prevent one serious bleed, consistent with the 6 patients needed to be treated with DrugSorb-ATR to see a similar benefit observed in the STAR-T trial. The analysis, proposed by FDA in last year’s appeal meeting, is expected to form the core of additional data to support probable benefit of the device in a new De Novo submission, increasing the number of CABG patients on Brilinta to nearly 700, including both treated and control patients from both the STAR-T randomized controlled trial and these new data. Meanwhile, the company is working with the FDA on an additional animal study to provide mechanistic data for this submission. In parallel, the company is advancing a separate De Novo pathway for removing direct oral anticoagulants, including Eliquis and Xarelto. Together, the Brilinta and direct oral anticoagulant programs represent two distinct potential pathways to U.S. commercialization and significant market expansion.

4. Unlocking the Strategic Value of HemoDefend-BGA

The company’s fourth value driver is realizing the strategic importance of HemoDefend-BGA, a differentiated blood purification technology developed with approximately $16 million in prior non-dilutive U.S. government funding. The technology is designed to remove anti-A and anti-B antibodies from plasma and platelet products, potentially enabling universal blood products that can be transfused regardless of recipient blood type without the need for electricity, specialized equipment or complex processing. This could simplify hospital inventory management, reduce waste and costs, and ultimately enable first responders, military units and ambulances to carry freeze-dried universal plasma without refrigeration or blood typing.

Following favorable FDA feedback in July regarding the anticipated clinical development pathway, the company is evaluating opportunities to advance HemoDefend-BGA through additional government funding, commercial partnerships, licensing arrangements and other strategic alternatives. Management believes the technology represents an underrecognized asset with meaningful potential to create shareholder value without requiring substantial cash investments.

Valuation and Estimates

In the 4th quarter of 2025, the company implemented a strategic workforce and cost reduction program which reduced headcount by 10% while also lowering expenses and realigning operating and production spend. As previously guided, the company has now achieved operating cash flow breakeven in the third quarter of 2026, hitting $43,000 of positive operating cash flow after restructuring costs, and plans to maintain the business within a range of operating breakeven moving forward, subject to quarter-to-quarter variability.

Beginning in 2025, the company began a significant reorganization of the direct sales team and strategy in Germany (its largest market for the CytoSorb device). This includes the rebalancing of territories and hospital accounts with the goal of restoring sales growth through deeper customer engagement, more effective market development, and improved sales representative productivity. Although the rebuilding phase of the German sales team is ongoing, the company remains confident it will lead to stronger execution, improved performance, and better sales growth in the region.

We adjust our price target to $50.00 per share due to the uncertainty of the timing of the DrugSorb-ATR submission and subsequent approval (if approved) in 2027, the timeline for positive organic revenue growth in Germany, as well as higher interest rates.

We believe the company has adequate liquidity and funding options to support its business model through the expected regulatory approval of DrugSorb-ATR and the subsequent commercial launch in 2027.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

Multimedia Files:

Categories: Press Releases
View all news